0000000000886771

AUTHOR

Maria Adele Giamberardino

showing 2 related works from this author

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

2011

The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints w…

AdultMaleAdolescentOriginalMigraine with AuraPopulationAlmotriptanCarbazolesClinical NeurologyMigraine; almotriptan; FrovatriptanYoung Adultalmotriptan; frovatriptan; migraine; patient preferenceDouble-Blind MethodAlmotriptanmedicineHumansMigraine Frovatriptan Almotriptan Patient preferencePatient preferenceeducationMigraineAgededucation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyRizatriptanTryptaminesMigraine with auraSerotonin Receptor AgonistsalmotriptanTreatment OutcomeAnesthesiology and Pain MedicineItalyMigraineTolerabilityAnesthesiaAcute DiseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptombusinessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study

2013

Results 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2and 4-hrs was 36% and 53% for frovatriptan and 41% and 50% for almotriptan (p=NS between treatments). Rate of pain free at 2and 4-hrs was 19% and 47% with frovatriptan and 29% and 54% for almotriptan (p=NS). At 24-hrs, 62% of frovatriptanand 67% of almotriptan-treated patients had pain relief, while 60% vs. 67% were pain free (p=NS). Recurrence at 24-hrs was significantly (p<0.05) lower with f…

medicine.medical_specialtyeducation.field_of_studyTraditional medicinebusiness.industrymedia_common.quotation_subjectPopulationPain reliefClinical NeurologySubgroup analysisGeneral Medicinemedicine.diseaseAnesthesiology and Pain MedicineMigraineInternal medicineAlmotriptanFemale patientPoster PresentationmedicineNeurology (clinical)FrovatriptaneducationbusinessMenstrual cyclemedicine.drugmedia_commonThe Journal of Headache and Pain
researchProduct